Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 5, 2001, Pages 1431-1437

  Climo, M W ^a   Ehlert, K ^a   Archer, G L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; GLYCINE; LYSOSTAPHIN; NAFCILLIN; OXACILLIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SIMULANS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; LYSOSTAPHIN; MICROBIAL SENSITIVITY TESTS; MUTATION; OXACILLIN; PENICILLINS; PEPTIDES; STAPHYLOCOCCUS AUREUS;

EID: 0035040527     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.5.1431-1437.2001     Document Type: Article

References (30)

1. femA, a host-mediated factor essential for methicllin resistance in Staphylocccus aureus: Molecular cloning and characterization
2. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
3. Identification and characterization of the origin of conjugal transfer (oriT) and a gene (nes) encoding a single-stranded endonuclease on the staphylococcal plasmid pGO1
4. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis
5. Comparison of in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species
6. Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus
7. Lysostaphin: An enzymatic approach to staphylococcal disease. III. Combined lysostaphin-oxacillin therapy of established staphylococcal abscesses in mice
8. Methicillin-resistance in Staphylococcus aureus - Molecular basis, novel targets and antibiotic therapy
9. Specificities of FemA and FemB for different glycine residues: FemB cannot substitute for FemA in staphylococcal peptidoglycan pentaglycine side chain formation
10. Site-specific serine incorporation by Lif and Epr into positions 3 and 5 of the staphylococcal petidoglycan interpeptide bridge
11. Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin
12. Therapeutic activity of lysostaphin in experimental staphylococcal infections
13. Lysostaphin in experimental renal infections
14. Influence of femB on methicillin resistance and peptidoglycan metabolism in Staphylococcus aureus
15. Oxacillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
16. Staphylococcal petidoglycan interpeptide bridge biosynthesis: A novel antistaphylococcal target?
17. femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicllin-resistant and oxacillin-susceptible Staphyloccoccus aureus strains
18. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically
19. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibtility to vancomycin
20. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart
21. The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation
22. Lysostaphin: An enzymatic approach to staphylococcal disease. II. In vivo studies
23. Lysostaphin: An enzymatic approach to staphylococcal disease. I. In vitro studies
24. Lysostaphin therapy in mice infected with Staphylococcus aureus
25. Systemic lysostaphin in man. Apparent antimicrobial activity in a neutropenic patient
26. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicllin-resistant Staphyloocccus aureus
27. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
28. Lif, the lysostaphin immunity factor, complements FemB in staphylococcal peptidoglycan interpeptide bridge formation
29. Identification of three additional femAB-like open reading frames in Staphylococcus aureus
30. Lysostaphin: Model for a specific enzymatic approach to infectious disease